Chronic myelomonocytic leukemia: Forefront of the field in 2015

被引：17
作者：
Benton, Christopher B. [1 ]
Nazha, Aziz [2 ]
Pemmaraju, Naveen [3 ]
Garcia-Manero, Guillermo [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Cleveland Clin, Leukemia Program, Dept Hematol Oncol & Blood Disorders, Taussig Canc Inst, Cleveland, OH 44106 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 95卷 / 02期
关键词：
Chronic myelomonocytic leukemia; Myelodysplastic syndrome; Myeloproliferative neoplasms; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; PRIMARY MYELODYSPLASTIC SYNDROMES; CYTOGENETIC RISK STRATIFICATION; FARNESYL TRANSFERASE INHIBITOR; TOPOISOMERASE-I INHIBITOR; WORLD-HEALTH-ORGANIZATION; TYROSINE KINASE JAK2; GROWTH-FACTOR; BONE-MARROW;
D O I：
10.1016/j.critrevonc.2015.03.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chronic myelomonocytic leukemia (CMML) includes components of both myelodysplastic syndrome and myeloproliferative neoplasms and is associated with a characteristic peripheral monocytosis. CMML is caused by the proliferation of an abnormal hematopoietic stem cell clone and may be influenced by microenvironmental changes. The disease is rare and has undergone revisions in its classification. We review the recent classification strategies as well as diagnostic criteria, focusing on CMML's genetic alterations and unique pathophysiology. We also discuss the latest molecular characterization of the disease, including how molecular factors affect current prognostic models. Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies. (C) 2015 Published by Elsevier Ireland Ltd.
引用
收藏
页码：222 / 242
页数：21
相关论文
共 179 条
  • [1] Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
    Abdel-Wahab, Omar
    Gao, Jie
    Adli, Mazhar
    Dey, Anwesha
    Trimarchi, Thomas
    Chung, Young Rock
    Kuscu, Cem
    Hricik, Todd
    Ndiaye-Lobry, Delphine
    LaFave, Lindsay M.
    Koche, Richard
    Shih, Alan H.
    Guryanova, Olga A.
    Kim, Eunhee
    Li, Sheng
    Pandey, Suveg
    Shin, Joseph Y.
    Telis, Leon
    Liu, Jinfeng
    Bhatt, Parva K.
    Monette, Sebastien
    Zhao, Xinyang
    Mason, Christopher E.
    Park, Christopher Y.
    Bernstein, Bradley E.
    Aifantis, Iannis
    Levine, Ross L.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (12) : 2641 - 2659
  • [2] ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
    Abdel-Wahab, Omar
    Adli, Mazhar
    LaFave, Lindsay M.
    Gao, Jie
    Hricik, Todd
    Shih, Alan H.
    Pandey, Suveg
    Patel, Jay P.
    Chung, Young Rock
    Koche, Richard
    Perna, Fabiana
    Zhao, Xinyang
    Taylor, Jordan E.
    Park, Christopher Y.
    Carroll, Martin
    Melnick, Ari
    Nimer, Stephen D.
    Jaffe, Jacob D.
    Aifantis, Iannis
    Bernstein, Bradley E.
    Levine, Ross L.
    [J]. CANCER CELL, 2012, 22 (02) : 180 - 193
  • [3] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    Aguayo, A
    Kantarjian, H
    Manshouri, T
    Gidel, C
    Estey, E
    Thomas, D
    Koller, C
    Estrov, Z
    O'Brien, S
    Keating, M
    Freireich, E
    Albitar, M
    [J]. BLOOD, 2000, 96 (06) : 2240 - 2245
  • [4] Expression of the proliferation-associated nuclear protein lNUB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes
    Alexandrakis, MG
    Passam, FH
    Kyriakou, DS
    Dambaki, C
    Katrinakis, GE
    Tsirakis, G
    Konsolas, J
    Stathopoulos, EN
    [J]. JOURNAL OF MOLECULAR HISTOLOGY, 2004, 35 (8-9) : 857 - 863
  • [5] Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes
    Alexandrakis, MG
    Passam, FH
    Pappa, CA
    Sfiridaki, K
    Tsirakis, G
    Damilakis, J
    Stathopoulos, EN
    Kyriakou, DS
    [J]. LEUKEMIA RESEARCH, 2005, 29 (01) : 41 - 46
  • [6] Alsahlawi A, 2014, CLIN LYMPHOMA MYELOM, V15, pe39
  • [7] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Apperley, JF
    Gardembas, M
    Melo, JV
    Russell-Jones, R
    Bain, BJ
    Baxter, J
    Chase, A
    Chessells, JM
    Colombat, M
    Dearden, CE
    Dimitrijevic, S
    Mahon, FX
    Marin, D
    Nikolova, Z
    Olavarria, E
    Silberman, S
    Schultheis, B
    Cross, NCP
    Goldman, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 481 - 487
  • [8] Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
    Aribi, Ahmed
    Borthakur, Gautam
    Ravandi, Farhad
    Shan, Jianqin
    Davisson, Jan
    Gortes, Jorge
    Kantarjian, Hagop
    [J]. CANCER, 2007, 109 (04) : 713 - 717
  • [9] Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia
    Aucagne, Romain
    Droin, Nathalie
    Paggetti, Jerome
    Lagrange, Brice
    Largeot, Anne
    Hammann, Arlette
    Bataille, Amandine
    Martin, Laurent
    Yan, Kai-Ping
    Fenaux, Pierre
    Losson, Regine
    Solary, Eric
    Bastie, Jean-Noel
    Delva, Laurent
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) : 2361 - 2370
  • [10] AUL C, 1992, LEUKEMIA, V6, P52
12345678910